Daniel J. DeAngelo, MD, PhD, director of clinical and translational research, Adult Leukemia Institute (ALL), Dana-Farber Cancer Institute, discusses inotuzumab ozogamicin compared to standard chemotherapy in the INO-VATE study for patients with acute lymphoblastic leukemia (ALL).
Inotuzumab ozogamicin is an anti—CD22 antibody-drug conjugate. Over 90% of patients with B-cell ALL express CD-22 on their surface. Several phase I and II studies showed that inotuzumab ozogamicin had very high clinical activity/
In the phase III trial INO-VATE trial inotuzumab ozogamicin demonstrated a median PFS of 5.0 months (95% CI, 3.7-5.6) compared with 1.8 months (95% CI, 1.5-2.2) with standard chemotherapy (HR, 0.45; 97.5% CI, 0.34-0.61; P <.001)
The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 80.7% with inotuzumab ozogamicin (95% CI, 72.1-88.7) compared with 29.4% of those who received standard chemotherapy (95% CI, 21.0-38.8; P <.001).